patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_591314 | REC_0015001 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7.7 | 70 | female | 3 | 30 | 5.6 | 2 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:01.008307+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177821 | REC_0015002 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 10.8 | 63 | female | 1 | 33 | 6.8 | 1 | alectinib 600 mg BID | 14.5 | false | MSI-H | 2026-03-15T05:36:01.008709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_861494 | REC_0015003 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 9.7 | 52 | female | 0 | 15 | 3.5 | 8 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:36:01.009390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449945 | REC_0015004 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 14.4 | 55 | male | 1 | 6 | 4.3 | 5 | entrectinib 600 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:36:01.009863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452418 | REC_0015005 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 11.2 | 55 | male | 1 | 14 | 4.1 | 2 | osimertinib 80 mg daily | 16.1 | false | MSS | 2026-03-15T05:36:01.010263+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140036 | REC_0015006 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.5 | 76 | female | 3 | 41 | 5.6 | 4 | pembrolizumab 200 mg q3w | 5.9 | true | MSS | 2026-03-15T05:36:01.010616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658666 | REC_0015007 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 12.3 | 72 | female | 0 | 10 | 7.9 | 3 | entrectinib 600 mg daily | 6.7 | true | MSS | 2026-03-15T05:36:01.010991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141484 | REC_0015008 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9.1 | 62 | male | 1 | 12 | 3.9 | 8 | alectinib 600 mg BID | 13.9 | false | MSS | 2026-03-15T05:36:01.011319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864164 | REC_0015009 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.6 | 62 | male | 0 | 7 | 5.8 | 1 | osimertinib 80 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:01.011682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786978 | REC_0015010 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 18.8 | 70 | female | 1 | 13 | 6.4 | 6 | entrectinib 600 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:36:01.012069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328770 | REC_0015011 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 14.4 | 75 | male | 1 | 10 | 4.5 | 6 | sotorasib 960 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:01.012550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467465 | REC_0015012 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 8 | 59 | female | 0 | 20 | 3.6 | 1 | pembrolizumab 200 mg q3w | 18.5 | false | MSS | 2026-03-15T05:36:01.012951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948524 | REC_0015013 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.9 | 67 | female | 0 | 10 | 4.9 | 6 | osimertinib 80 mg daily | 19.2 | true | MSS | 2026-03-15T05:36:01.013371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350083 | REC_0015014 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 9.8 | 82 | female | 1 | 9 | 7.8 | 2 | osimertinib 80 mg daily | 19.8 | true | MSS | 2026-03-15T05:36:01.013807+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796118 | REC_0015015 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 16 | 70 | male | 1 | 17 | 6.5 | 7 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:01.014205+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605654 | REC_0015016 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.9 | 85 | female | 1 | 27 | 4.4 | 6 | sotorasib 960 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:01.014756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381211 | REC_0015017 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.2 | 51 | male | 0 | 11 | 5.1 | 6 | osimertinib 80 mg daily | 8.2 | true | MSI-H | 2026-03-15T05:36:01.015493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232490 | REC_0015018 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 12.5 | 73 | female | 2 | 19 | 7.6 | 0 | sotorasib 960 mg daily | 27.7 | false | MSS | 2026-03-15T05:36:01.015924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359454 | REC_0015019 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 14.7 | 65 | male | 0 | 22 | 4.5 | 2 | alectinib 600 mg BID | 20.2 | true | MSS | 2026-03-15T05:36:01.016412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606343 | REC_0015020 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 9.2 | 65 | male | 1 | 18 | 6.6 | 7 | sotorasib 960 mg daily | 14.4 | true | MSS | 2026-03-15T05:36:01.016810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607891 | REC_0015021 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 10 | 66 | female | 0 | 9 | 6.2 | 1 | osimertinib 80 mg daily | 30 | false | MSS | 2026-03-15T05:36:01.017165+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454641 | REC_0015022 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 1.5 | 74 | female | 1 | 10 | 3.2 | 1 | pembrolizumab 200 mg q3w | 9.5 | true | MSS | 2026-03-15T05:36:01.017527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302523 | REC_0015023 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 5.3 | 65 | male | 1 | 14 | 4 | 7 | pembrolizumab 200 mg q3w | 12 | true | MSS | 2026-03-15T05:36:01.018106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255063 | REC_0015024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 15 | 57 | female | 1 | 22 | 4.8 | 4 | alectinib 600 mg BID | 13.7 | false | MSI-H | 2026-03-15T05:36:01.018529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147026 | REC_0015025 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 16 | 52 | male | 0 | 10 | 4.7 | 5 | alectinib 600 mg BID | 4.3 | false | MSS | 2026-03-15T05:36:01.018941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116783 | REC_0015026 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 1.5 | 77 | male | 2 | 48 | 7 | 8 | pembrolizumab 200 mg q3w | 4.5 | true | MSS | 2026-03-15T05:36:01.021620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144568 | REC_0015027 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 12.2 | 53 | female | 0 | 7 | 5 | 1 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:01.022211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138514 | REC_0015028 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 17 | 65 | male | 0 | 11 | 6.8 | 2 | osimertinib 80 mg daily | 15 | false | MSI-H | 2026-03-15T05:36:01.022693+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605270 | REC_0015029 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 8.5 | 71 | female | 1 | 11 | 6.2 | 1 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:36:01.023342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813204 | REC_0015030 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 5 | 61 | male | 1 | 4 | 6.6 | 4 | osimertinib 80 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:01.023776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_890221 | REC_0015031 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 14.8 | 65 | male | 0 | 21 | 5.2 | 6 | sotorasib 960 mg daily | 4.2 | false | MSI-H | 2026-03-15T05:36:01.024252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755380 | REC_0015032 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9 | 62 | male | 1 | 23 | 5 | 7 | entrectinib 600 mg daily | 13.6 | false | MSS | 2026-03-15T05:36:01.024670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925500 | REC_0015033 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.6 | 58 | male | 0 | 9 | 7.2 | 5 | osimertinib 80 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:01.025057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106455 | REC_0015034 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.7 | 56 | female | 0 | 6 | 5.4 | 6 | alectinib 600 mg BID | 11.8 | false | MSS | 2026-03-15T05:36:01.025431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563231 | REC_0015035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 20.6 | 68 | female | 1 | 13 | 6.5 | 2 | entrectinib 600 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:36:01.025797+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883285 | REC_0015036 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.6 | 73 | female | 3 | 15 | 5.4 | 7 | osimertinib 80 mg daily | 14.9 | true | MSS | 2026-03-15T05:36:01.026200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493438 | REC_0015037 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 2.2 | 61 | male | 1 | 23 | 3.5 | 2 | entrectinib 600 mg daily | 18.6 | true | MSS | 2026-03-15T05:36:01.026590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147132 | REC_0015038 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 7.9 | 59 | male | 0 | 16 | 7.8 | 2 | osimertinib 80 mg daily | 21.2 | true | MSS | 2026-03-15T05:36:01.026966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528727 | REC_0015039 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.5 | 73 | female | 2 | 20 | 8.1 | 2 | osimertinib 80 mg daily | 22.9 | false | MSI-H | 2026-03-15T05:36:01.027312+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558872 | REC_0015040 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.4 | 85 | female | 2 | 30 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:36:01.027653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723533 | REC_0015041 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 2.6 | 71 | female | 2 | 16 | 5.8 | 3 | sotorasib 960 mg daily | 9.8 | true | MSS | 2026-03-15T05:36:01.027998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750055 | REC_0015042 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 15 | 14 | 72 | female | 1 | 23 | 6.8 | 1 | osimertinib 80 mg daily | 25.1 | false | MSI-H | 2026-03-15T05:36:01.028603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320499 | REC_0015043 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.2 | 65 | male | 1 | 68 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:36:01.029029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_314552 | REC_0015044 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 14.4 | 68 | male | 0 | 18 | 5 | 4 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:01.029409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739937 | REC_0015045 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.9 | 59 | male | 1 | 20 | 5.7 | 2 | entrectinib 600 mg daily | 7 | true | MSI-H | 2026-03-15T05:36:01.029771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488956 | REC_0015046 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 3.9 | 76 | female | 2 | 27 | 6 | 2 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:36:01.030147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698910 | REC_0015047 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.1 | 84 | female | 2 | 11 | 5.5 | 6 | sotorasib 960 mg daily | 8 | true | MSI-H | 2026-03-15T05:36:01.030564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149712 | REC_0015048 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12 | 71 | female | 2 | 20 | 5.7 | 4 | osimertinib 80 mg daily | 16.2 | true | MSI-H | 2026-03-15T05:36:01.030940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701848 | REC_0015049 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5.7 | 60 | female | 0 | 44 | 4 | 2 | pembrolizumab 200 mg q3w | 17.3 | true | MSS | 2026-03-15T05:36:01.031287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623063 | REC_0015050 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 4.8 | 64 | female | 1 | 44 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 8.7 | true | MSS | 2026-03-15T05:36:01.031893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356335 | REC_0015051 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 14.9 | 70 | female | 2 | 10 | 4.3 | 1 | alectinib 600 mg BID | 13.6 | true | MSS | 2026-03-15T05:36:01.032407+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459010 | REC_0015052 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 7.9 | 51 | male | 0 | 16 | 6.2 | 2 | osimertinib 80 mg daily | 28.6 | true | MSS | 2026-03-15T05:36:01.032841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_866040 | REC_0015053 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.3 | 78 | female | 1 | 11 | 6.7 | 3 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:36:01.033269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460749 | REC_0015054 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12 | 70 | female | 1 | 4 | 4.4 | 6 | osimertinib 80 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:36:01.033681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262290 | REC_0015055 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 19 | 68 | male | 0 | 10 | 7.1 | 4 | osimertinib 80 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:36:01.034301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747396 | REC_0015056 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.6 | 79 | female | 1 | 50 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 17.1 | true | MSS | 2026-03-15T05:36:01.034699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618543 | REC_0015057 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 7.1 | 75 | female | 2 | 29 | 3.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.3 | false | MSS | 2026-03-15T05:36:01.035087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996405 | REC_0015058 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.6 | 63 | female | 1 | 25 | 5.5 | 6 | sotorasib 960 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:01.035479+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_969045 | REC_0015059 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 9.3 | 63 | male | 1 | 15 | 5.9 | 6 | entrectinib 600 mg daily | 9 | false | MSS | 2026-03-15T05:36:01.035845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807999 | REC_0015060 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.8 | 89 | male | 2 | 50 | 4.7 | 4 | pembrolizumab 200 mg q3w | 5.2 | true | MSS | 2026-03-15T05:36:01.036260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975897 | REC_0015061 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 9.3 | 78 | female | 1 | 5 | 8.1 | 5 | sotorasib 960 mg daily | 7.2 | false | MSS | 2026-03-15T05:36:01.036611+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_848701 | REC_0015062 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.1 | 56 | female | 0 | 35 | 6 | 4 | pembrolizumab 200 mg q3w | 18.2 | false | MSS | 2026-03-15T05:36:01.037001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885662 | REC_0015063 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 8.2 | 51 | female | 0 | 39 | 4 | 5 | pembrolizumab 200 mg q3w | 21.6 | true | MSS | 2026-03-15T05:36:01.037406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900065 | REC_0015064 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6 | 67 | male | 1 | 13 | 2.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:36:01.037820+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276902 | REC_0015065 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.6 | 69 | female | 1 | 23 | 5.5 | 4 | sotorasib 960 mg daily | 16.5 | false | MSS | 2026-03-15T05:36:01.038187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_156242 | REC_0015066 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 12.4 | 68 | female | 0 | 14 | 5.2 | 6 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:36:01.038552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107472 | REC_0015067 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 9.7 | 73 | female | 3 | 12 | 5.4 | 4 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:36:01.038902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826319 | REC_0015068 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.1 | 67 | female | 1 | 7 | 4.1 | 5 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:36:01.039445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976415 | REC_0015069 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 20.1 | 82 | female | 1 | 21 | 5.8 | 2 | osimertinib 80 mg daily | 17.8 | true | MSS | 2026-03-15T05:36:01.039861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771578 | REC_0015070 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.8 | 79 | male | 1 | 13 | 4.9 | 5 | alectinib 600 mg BID | 15.5 | false | MSS | 2026-03-15T05:36:01.040602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534328 | REC_0015071 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 10.1 | 53 | female | 0 | 9 | 6.3 | 2 | osimertinib 80 mg daily | 13.3 | false | MSI-H | 2026-03-15T05:36:01.041087+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647759 | REC_0015072 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 9.7 | 62 | male | 1 | 20 | 5.4 | 1 | osimertinib 80 mg daily | 22.6 | false | MSS | 2026-03-15T05:36:01.041494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567419 | REC_0015073 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 13.4 | 59 | female | 1 | 10 | 5.7 | 1 | alectinib 600 mg BID | 15.2 | true | MSS | 2026-03-15T05:36:01.041894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243917 | REC_0015074 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 2.2 | 64 | female | 0 | 20 | 4.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 19 | false | MSS | 2026-03-15T05:36:01.042294+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220551 | REC_0015075 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 10.5 | 66 | female | 1 | 15 | 3.1 | 7 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:36:01.042694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918851 | REC_0015076 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 17 | 9.1 | 61 | male | 0 | 12 | 5.6 | 0 | entrectinib 600 mg daily | 46 | false | MSS | 2026-03-15T05:36:01.043125+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390850 | REC_0015077 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.3 | 73 | female | 2 | 7 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 4.3 | false | MSS | 2026-03-15T05:36:01.043584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892456 | REC_0015078 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 18.2 | 73 | female | 2 | 26 | 3.9 | 5 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:36:01.043986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948119 | REC_0015079 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 4.5 | 71 | female | 2 | 17 | 5.5 | 4 | entrectinib 600 mg daily | 8.9 | false | MSS | 2026-03-15T05:36:01.044558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196642 | REC_0015080 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12.7 | 54 | male | 0 | 5 | 6.5 | 7 | entrectinib 600 mg daily | 5.4 | true | MSS | 2026-03-15T05:36:01.044970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300942 | REC_0015081 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.7 | 57 | male | 1 | 12 | 5.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:36:01.045586+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618292 | REC_0015082 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 29 | 4.2 | 61 | male | 0 | 50 | 7.7 | 0 | carboplatin + paclitaxel + pembrolizumab | 24.5 | false | MSS | 2026-03-15T05:36:01.046045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780289 | REC_0015083 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 14 | 67 | female | 0 | 13 | 7.2 | 0 | sotorasib 960 mg daily | 28.4 | true | MSS | 2026-03-15T05:36:01.046462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332299 | REC_0015084 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 14.2 | 73 | male | 2 | 15 | 7.2 | 1 | sotorasib 960 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:01.046841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341248 | REC_0015085 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 14.7 | 53 | female | 0 | 23 | 7 | 5 | pembrolizumab 200 mg q3w | 9.2 | true | MSI-H | 2026-03-15T05:36:01.047237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456950 | REC_0015086 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 9.8 | 77 | male | 1 | 20 | 6.7 | 6 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:36:01.047634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721945 | REC_0015087 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 5.9 | 67 | female | 1 | 54 | 4.9 | 5 | pembrolizumab 200 mg q3w | 14.7 | true | MSS | 2026-03-15T05:36:01.048026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596517 | REC_0015088 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 18.6 | 75 | female | 2 | 14 | 7.1 | 2 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:01.048762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697846 | REC_0015089 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 14.1 | 69 | female | 0 | 14 | 4.3 | 5 | entrectinib 600 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.049168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889467 | REC_0015090 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11 | 76 | female | 1 | 12 | 5.1 | 6 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:36:01.049575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970317 | REC_0015091 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 13.9 | 78 | female | 2 | 13 | 2.8 | 5 | osimertinib 80 mg daily | 14.5 | true | MSS | 2026-03-15T05:36:01.049953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474982 | REC_0015092 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 13.7 | 60 | female | 0 | 22 | 7.5 | 5 | pembrolizumab 200 mg q3w | 11 | false | MSI-H | 2026-03-15T05:36:01.050297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179837 | REC_0015093 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 9.4 | 59 | female | 0 | 8 | 5.6 | 6 | entrectinib 600 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:01.050657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309949 | REC_0015094 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 12.5 | 72 | female | 2 | 12 | 5.2 | 5 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:36:01.051184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849895 | REC_0015095 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.7 | 68 | female | 1 | 34 | 4.7 | 9 | pembrolizumab 200 mg q3w | 15.8 | true | MSS | 2026-03-15T05:36:01.051608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234162 | REC_0015096 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8 | 73 | male | 0 | 59 | 5.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.4 | false | MSS | 2026-03-15T05:36:01.051988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117303 | REC_0015097 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 32 | 7.2 | 52 | male | 0 | 11 | 6.8 | 1 | pembrolizumab 200 mg q3w | 19.3 | true | MSS | 2026-03-15T05:36:01.052489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708777 | REC_0015098 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 21 | 12.3 | 53 | female | 0 | 9 | 7.9 | 0 | pembrolizumab 200 mg q3w | 43.2 | false | MSS | 2026-03-15T05:36:01.052876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607199 | REC_0015099 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 6.7 | 66 | female | 0 | 10 | 2.7 | 5 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:36:01.053253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193897 | REC_0015100 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 16.8 | 60 | female | 1 | 18 | 4.9 | 5 | alectinib 600 mg BID | 7.5 | false | MSS | 2026-03-15T05:36:01.053629+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.